0001104659-22-069921.txt : 20220610 0001104659-22-069921.hdr.sgml : 20220610 20220610083708 ACCESSION NUMBER: 0001104659-22-069921 CONFORMED SUBMISSION TYPE: 15-12B PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220610 DATE AS OF CHANGE: 20220610 EFFECTIVENESS DATE: 20220610 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Checkmate Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001651431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 364813934 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12B SEC ACT: 1934 Act SEC FILE NUMBER: 001-39425 FILM NUMBER: 221007716 BUSINESS ADDRESS: STREET 1: 245 MAIN STREET, 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 978-503-2124 MAIL ADDRESS: STREET 1: 245 MAIN STREET, 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 15-12B 1 tm2217167d6_1512b.htm 15-12B

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER

SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY

TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-39425

Checkmate Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

245 Main Street, 2nd Floor

Cambridge, MA 02142

(617) 682-3625

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, par value $0.0001 per share

(Title of each class of securities covered by this Form)

N/A

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)	x
Rule 12g-4(a)(2)	¨
Rule 12h-3(b)(1)(i)	x
Rule 12h-3(b)(1)(ii)	¨
Rule 15d-6	¨
Rule 15d-22(b)	¨

Approximate number of holders of record as of the certification or notice date: one (1).

Pursuant to the requirements of the Securities Exchange Act of 1934, Checkmate Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: June 10, 2022	Checkmate Pharmaceuticals, Inc.

	By:	/s/ Nouhad Husseini
	Name:	Nouhad Husseini
	Title:	Managing Director